biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > A Chance

<< Previous

Bullboard Posts

Next >>

Post by KayakerBCon Dec 23, 2022 1:58pm

166 Views

Post# 35190012

A Chance

There are 10s of millions of BTI shares that will give this a chance. Mostly because we have no choice. But they've got less than a year IMO. This time next year, if Biodexa is not substantially higher, most of those 10s of millions of BTI shares will have already hit the exit for the tax loss. I suspect Biodexa will have limited liquidity so it won't be pretty.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing